Search results

IEA Task 26 Solar Combisystems. Report on description and helptext for the Software Combisun

Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

The first meeting of international specialists in the field of von Willebrand disease (VWD) was held in the Åland islands in 1998 where Erik von Willebrand had first observed a bleeding disorder in some members of a family from Föglö and a summary of the meeting was published in 1999. The second meeting was held in 2010 and a report of the meeting was published in 2012. Topics covered included pro

Swanson versus apl arthroplasty in the treatment of osteoarthritis of the trapeziometacarpal joint: a prospective and randomized study in 26 patients.

Twenty-six patients were operated because of osteo-arthritis of the trapeziometacarpal joint. After excision of the trapezium, they were randomized to receive either a Swanson silicone trapezium implant or a tendon interposition arthroplasty using a strip of the abductor pollicis longus tendon (APL). No infection or clinical silicone synovitis occurred and no major radiographic cyst formation was

Rifm fragrance ingredient safety assessment, (2E,6Z)-Nona-2,6-dien-1-ol, CAS registry number 28069-72-9.

RIFM fragrance ingredient safety assessment phenethyl isovalerate, CAS Registry Number 140-26-1

RIFM fragrance ingredient safety assessment, 2-(3,7-dimethyl-2,6-octadienyl)cyclopentanone, CAS Registry Number 68133-79-9

RIFM fragrance ingredient safety assessment, 3,7-dimethyl-2,6-nonadien-1-al, CAS Registry Number 41448-29-7

RIFM fragrance ingredient safety assessment, 2,6,6-trimethylcyclohexa-1,3-dienyl methanal, CAS Registry Number 116-26-7

A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1

Workshop on Feedback and Synthesis of Linear Systems, Bielefeld, Germany, June 22-26, 1981

Report of Lund University Center for Middle Eastern Studies' Visit to Hungary, 25-26 May 2017

Severe fetal growth restriction at 26–32 weeks : key messages from the TRUFFLE study

RIFM FRAGRANCE INGREDIENT SAFETY ASSESSMENT, 2,6-Dimethylocta-2,4,6-triene, CAS Registry Number 673-84-7

RIFM fragrance ingredient safety assessment, 5,9-dimethyl-4,8-decadienal, CAS Registry Number 762-26-5

Natural Radiative Lifetimes of Some Excited Bi I Levels Belonging to the 6p^(2)7s and the 6p^(2)6d Configurations Measured by the Hanle Method

The natural radiative lifetimes of some excited Bi I levels belonging to the 6 p 2 7 s and the 6 p 2 6 d configurations have been determined by analyzing Hanle depolarization curves obtained in an atomic beam experiment on the 100% abundant isotope Bi 209 ( I =9/2). Taking the exciting light spectral distribution into account the following values for the lifetimes have been obtained: ##IMG## [http

"The importance of good linkwork. Experiences from integration projects in Malmö, Sweden." in ENHR Conference in Tirana, 26-28 May 2003. Tirana: Department of Sociology, Lund University.

Beta Decay of Ne-26

The laws' properties (2001-11-26)

In this paper I develop a view of the distinction between fake and genuine properties occurring in laws of nature.

The light-yield response of a NE-213 liquid-scintillator detector measured using 2–6 MeV tagged neutrons

The response of a NE-213 liquid-scintillator detector has been measured using tagged neutrons from 2 to 6 MeV originating from an Am/Be neutron source. The neutron energies were determined using the time-of-flight technique. Pulse-shape discrimination was employed to discern between gamma-rays and neutrons. The behavior of both the fast (35 ns) and the combined fast and slow (475 ns) components of

Partnering to change the world for people with haemophilia : 6^th Haemophilia Global Summit, Prague, Czech Republic, 24–26^th September 2015

The 6th Haemophilia Global Summit was held in Prague, Czech Republic, in September 2015. The programme was designed by an independent Scientific Steering Committee of haemophilia experts and aimed to share optimal management strategies for haemophilia at all life stages, explore recent potential advances in the management of haemophilia A and B and discuss challenges in haemophilia care. In this s